Skip to main content
SpringerLink
Log in

Drug Eruptions

  • Chapter
Clinical and Basic Immunodermatology

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Stewart R, May F, Cullen S. Dermatologic adverse drug reactions in hospitalized patients. Am J Hosp Pharm 1979;36:609–12.

    PubMed  CAS  Google Scholar 

  2. Faich G, Knapp D, Dreis M, Turner W. National adverse drug reaction surveillance. JAMA 1987;257:2068–70.

    Article  PubMed  CAS  Google Scholar 

  3. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999;48:839–46.

    Article  PubMed  CAS  Google Scholar 

  4. Suh DC, Woodall BS, Shin SK, Hermes-DesSantis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000;34:1373–9.

    PubMed  CAS  Google Scholar 

  5. Arndt KA, Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1976;235:918–22.

    Article  PubMed  CAS  Google Scholar 

  6. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. JAMA 1986;256:3358–63.

    Article  PubMed  CAS  Google Scholar 

  7. Budnitz DS, Pollock DA, Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858–66.

    Article  PubMed  CAS  Google Scholar 

  8. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001;137:765–70.

    PubMed  CAS  Google Scholar 

  9. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoignw R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997;52:388–93.

    Article  PubMed  CAS  Google Scholar 

  10. Bachot N, Roujeau JC. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol 2003;4:561–72.

    Article  PubMed  Google Scholar 

  11. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev 2001;53:357–79.

    PubMed  CAS  Google Scholar 

  12. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sul-fonamides, phenytoin, and carbamazepine. J Immunol 1995;155:462–72.

    PubMed  CAS  Google Scholar 

  13. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111:1393–403.

    Article  PubMed  CAS  Google Scholar 

  14. Zanni M, Mauri-Hellweg D, Brander C, et al. Characterization of lidocaine-specific T cells. J Immunol 1997;158:1139–48.

    PubMed  CAS  Google Scholar 

  15. Chung WH, Hung SI, Hong HS, et al. A marker for Stevens-Johnson syndrome. Nature 2004;428:486.

    Article  PubMed  CAS  Google Scholar 

  16. Hettherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitiv-ity reactions to abacavir. Lancet 2002;359:1121–2.

    Article  Google Scholar 

  17. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004;5:203–11.

    Article  PubMed  CAS  Google Scholar 

  18. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005;102:4134–9.

    Article  PubMed  CAS  Google Scholar 

  19. Hung S-I, Chung W-H, Jee S-H, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006;16:297–306.

    Article  PubMed  CAS  Google Scholar 

  20. Uetrecht JP. Role of animal models in drug-induced hypersensitivity reactions. AAPS J 2005;7(4): E914–E21.

    Article  CAS  Google Scholar 

  21. Roujeau JC. Clinical heterogeneity of drug hypersen-sitivity. Toxicology 2005;209:123–9.

    Article  PubMed  CAS  Google Scholar 

  22. Yawalkar N. Drug-induced exanthemas. Toxicology 2005;209:131–4.

    Article  PubMed  CAS  Google Scholar 

  23. Crowson AN, Brown TJ, Margo CM. Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions. Am J Clin Dermatol 2003;4:407–28.

    Article  PubMed  Google Scholar 

  24. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019–24.

    Article  PubMed  Google Scholar 

  25. Vervloet D, Durham S. Adverse reactions to drugs. Br Med J 2006;316:1511–4.

    Google Scholar 

  26. Barbaud AM, Goncalo M, Bruynzeel D, Bircher A. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001;45:321–8.

    Article  PubMed  CAS  Google Scholar 

  27. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683–93.

    PubMed  CAS  Google Scholar 

  28. Khan FD, Roychowdhury S, Gaspari AA, Svensson CK. Immune response to xenobiotics in the skin: from contact sensitivity to drug allergy. Expert Opin Drug Metab Toxicol 2006;2:261–72.

    Article  PubMed  CAS  Google Scholar 

  29. Beeler A, Engler OB, Gerber BO, Pichler WJ. Long-lasting reactivity and high frequency of drug-specific T cells after severe systemic drug hypersensitivity reactions. J Allergy Clin Immunol 2006;117:455–62.

    Article  PubMed  CAS  Google Scholar 

  30. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114–9.

    Article  PubMed  CAS  Google Scholar 

  31. Gruchalla R. Drug metabolism, danger signals, and drug-induced hypersensitivity. J Allergy Clin Immunol 2001;108:475–88.

    Article  PubMed  CAS  Google Scholar 

  32. Haverkos H, Amsel Z, Drotman D. Adverse virus-drug reactions. Rev Infect Dis 1991;13:697–704.

    PubMed  CAS  Google Scholar 

  33. Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Safety 1997;16:1–8.

    Article  PubMed  CAS  Google Scholar 

  34. Warrington R, Sauder P, McPhillips S. Lymphocyte transformation studies in suspected hypersensitivity to trimethoprim-sulphamethoxazole. Clin Allergy 1983;13:235–40.

    Article  PubMed  CAS  Google Scholar 

  35. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy 2004;59:809–20.

    Article  PubMed  CAS  Google Scholar 

  36. Enk A, Katz S. Early molecular events in the induction phase of contact sensitivity. Proc Natl Acad Sci USA 1992;89:1398–402.

    Article  PubMed  CAS  Google Scholar 

  37. Grabbe S, Schwarz T. Immunoregulatory mechanisms involved in elicitation of allergic contact hypersensitivity. Immunol Today 1998;19:37–44.

    Article  PubMed  CAS  Google Scholar 

  38. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome—does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2001;136:323–7.

    Article  Google Scholar 

  39. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586–9.

    Article  PubMed  CAS  Google Scholar 

  40. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006;6:543–9.

    Article  PubMed  CAS  Google Scholar 

  41. Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255–9.

    Article  PubMed  CAS  Google Scholar 

  42. van der Linden P, van der Lei J, Vlug A, Stricker B. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998;51:703–8.

    Article  PubMed  Google Scholar 

  43. Chan H-L, Stern R, Arndt K, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43–7.

    Article  PubMed  CAS  Google Scholar 

  44. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272–85.

    Article  PubMed  CAS  Google Scholar 

  45. Roujeau JC, Kelly J P, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600–7.

    Article  PubMed  CAS  Google Scholar 

  46. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Safety 1999;21:489–501.

    Article  PubMed  CAS  Google Scholar 

  47. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843–8.

    Article  PubMed  CAS  Google Scholar 

  48. Gaspari A. The role of keratinocytes in the patho-physiology of contact dermatitis. Immunol Allergy Clin North Am 1997;17:377–405.

    Article  Google Scholar 

  49. Grone A. Keratinocytes and cytokines. Vet Immunol Immunopathol 2002;88:1–12.

    Article  PubMed  CAS  Google Scholar 

  50. Schwarzenberger K, Udey MC. Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J Invest Dermatol 1996;106:553–8.

    Article  PubMed  CAS  Google Scholar 

  51. Jakob T, Udey MC. Regulation of E-cadherin-medi-ated adhesion in Langerhans cell-like dendritic cells by inflammatory mediators that mobilize Langerhans cells in vivo. J Immunol 1998;160:4067–73.

    PubMed  CAS  Google Scholar 

  52. Jakob T, Ring J, Udey MC. Multistep navigation of Langerhans/dendritic cells in and out of the skin. J Allergy Clin Immunol 2001;108:688–96.

    Article  PubMed  CAS  Google Scholar 

  53. Lebre M, Kalinski P, Das P, Everts V. Inhibition of contact sensitizer-induced migration of human Langerhans cells by matrix metalloproteinase inhibitors. Arch Dermatol Res 1999;291:447–52.

    Article  PubMed  CAS  Google Scholar 

  54. Yanagihara S, Komura E, Nagafune J, Watarai H, Yamaguchi Y. EB11/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J Immunol 1998;161:3096–102.

    PubMed  CAS  Google Scholar 

  55. Robbiani D, Finch R, Jager D, Muller W, Sartorelli A, Randolph G. The leukotriene C4 transporter MRP1 regulates CCL19 (MIB-3b, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 2000;103:757–68.

    Article  PubMed  CAS  Google Scholar 

  56. Randolph G. Dendritic cell migration to lymph nodes: cytokines, chemokines, and lipid mediators. Semin Immunol 2001;13:267–74.

    Article  PubMed  CAS  Google Scholar 

  57. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol 2005;5:617–28.

    Article  PubMed  CAS  Google Scholar 

  58. Santamaria LF, Perez-Soler MT, Hauser C, Blasker K. Allergen specificity and endothelial transmigration of T cells in allergic contact dermatitic and atopic dermatitis are associated with the cutaneous lymphocyte antigen. Int Arch Allergy Appl Immunol 1995;107:359–62.

    CAS  Google Scholar 

  59. Kehren J, Desvignes C, Krasteva M, et al. Cytotoxicity is mandatory for CD8+ T cell-mediated contact hypersensitivity. J Exp Med 1999;189:779–86.

    Article  PubMed  CAS  Google Scholar 

  60. Albanesi C, Cavani A, Girolomoni G. Interferon-g-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules. J Invest Dermatol 1998;110:138–42.

    Article  PubMed  CAS  Google Scholar 

  61. Basham T, Nickoloff B, Merigan T, Morhenn V. Recombinant gamma interferon induces HLA-DR expression on cultured human keratinocytes. J Invest Dermatol 1984;83:88–90.

    Article  PubMed  CAS  Google Scholar 

  62. Dudda JC, Lembo A, Bachtanian E, et al. Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue micro-environments. Eur J Immunol 2005;35:1056–65.

    Article  PubMed  CAS  Google Scholar 

  63. Dudda JC, Simon JC, Martin S. Dendritic cell immunization route determines CD8+ T cell trafficking to inflammed skin: Role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 2004;172:857–63.

    PubMed  CAS  Google Scholar 

  64. Reilly TP, Lash LH, Doll MA, Hein DW, Woster PM, Svensson CK. A role for bioactivation and covalent binding within epidermal keratinocytes in sulfona-mide-induced cutaneous drug reactions. J Invest Dermatol 2000;114:1164–73.

    Article  PubMed  CAS  Google Scholar 

  65. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin Pharmacol Ther 1991;49:13–7.

    PubMed  CAS  Google Scholar 

  66. Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105: 179–84.

    PubMed  CAS  Google Scholar 

  67. Svensson CK. Do arylhydroxylamine metabolites mediate the idiosyncratic reactions associated with sulfonamides and sulfones? Chem Res Toxicol 2003;16:1034–43.

    Article  Google Scholar 

  68. Pirmohamed M, Alfirevic A, Vilar J, et al. Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity. Pharmacogenetics 2000;10:705–13.

    Article  PubMed  CAS  Google Scholar 

  69. Alfirevic A, Stalford AC, Vilar FJ, Wilkins EGL, Park BK, Pirmohamed M. Slow acetylator pheno-type and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity. Br J Clin Pharmacol 2003;55:158–65.

    Article  PubMed  CAS  Google Scholar 

  70. Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 2005;8(1):E20–E6.

    Article  Google Scholar 

  71. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002;359:727–32.

    Article  PubMed  CAS  Google Scholar 

  72. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004;101:4180–5.

    Article  PubMed  CAS  Google Scholar 

  73. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004;14:335–42.

    Article  PubMed  Google Scholar 

  74. Klemola E. Hypersensitivity reactions to ampicillin in cytomegalovirus mononucleosis. Scand J Infect Dis 1970;2:29–31.

    PubMed  CAS  Google Scholar 

  75. Nazareth I, Mortimer P, McKendrick GD. Ampicillin sensitivity in infectious mononucleosis - temporary or permanent? Scand J Infect Dis 1972;4:229–30.

    PubMed  CAS  Google Scholar 

  76. Patel BM. Skin rash with infectious mononucleosis and ampicillin. Pediatrics 1967;40:910–1.

    PubMed  CAS  Google Scholar 

  77. Pullen H, Wright N, Murdoch JM. Hypersensitivity reactions to antibacterial drugs in infectious mono-nucleosis. Lancet 1967;2:1176–8.

    Article  PubMed  CAS  Google Scholar 

  78. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495–9.

    PubMed  CAS  Google Scholar 

  79. Jaffe HS, Abrams DL, Ammann AJ, Lewis BJ, Golden JA. Complications of co-trimoxazole in treatment of AIDS-associated Pneumocystis carinii pneumonia in homosexual men. Lancet 1984;2:1009–11.

    Google Scholar 

  80. Roudier C, Caumes E, Rogeaux O, Bricaire F, Gentilini M. Adverse cutaneous reactions to trimeth-oprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome and Pneumocystis cari-nii pneumonia. Arch Dermatol 1994;130:1383–6.

    Article  PubMed  CAS  Google Scholar 

  81. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000;106:1171–6.

    Article  PubMed  CAS  Google Scholar 

  82. Yawalkar N, Egli F, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000;30:847–55.

    Article  PubMed  CAS  Google Scholar 

  83. Crowson AN, Margo CM. Recent advances in the pathology of cutaneous drug eruptions. Dermatol Clin 1999;17:537–60.

    Article  PubMed  CAS  Google Scholar 

  84. Blanca M, Posadas S, Torres MJ, et al. Expression of the skin-homing receptor in peripheral blood lymphocytes from subjects with non-immediate cutaneous allergic drug reactions. Allergy 2000;55: 998–1004.

    Article  PubMed  CAS  Google Scholar 

  85. Posadas SJ, Torres MJ, Mayorga C, Juarez C, Blanca M. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis 2002;29:179–89.

    Article  PubMed  Google Scholar 

  86. Villada G, Roujeau JC, Clerici T, Bourgault I, Revuz J. Immunopathology of toxic epidermal necrolysis. Keratinocytes, HLA-DR Expression, Langerhans Cells, and mononuclear cells: An immunopathologic study of five cases. Arch Dermatol 1992;128:50–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Nursing and Health Sciences, Purdue University West Lafayette, IN, USA

    Craig K. Svensson

Authors
  1. Craig K. Svensson
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, USA

    Anthony A. Gaspari MD

  2. Department of Dermatology, University of Texas Medical School at Houston, Houston, TX, USA

    Stephen K. Tyring MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Svensson, C.K. (2008). Drug Eruptions. In: Gaspari, A.A., Tyring, S.K. (eds) Clinical and Basic Immunodermatology. Springer, London. https://doi.org/10.1007/978-1-84800-165-7_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-84800-165-7_18

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84800-164-0

  • Online ISBN: 978-1-84800-165-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation